Neurology Specific Literature Search   
 
[home][thesaurus]
    

Enter your terms
above and click
the 'Search' button.
Showing articles 0 to 50 of 270 Next >>

Filter Applied: adverse drug reaction (Click to remove)

Severe Neurological Toxicity of Immune Checkpoint Inhibitors: Growing Spectrum
Ann Neurol 87:659-669, Dubey, D.,et al, 2020

Evidence-based Guideline: Intravenous Immunoglobulin in the Treatment of Neuromascular Disorders
Neurol 78:1009-1015, Patwa,H.S.,et al, 2012

Monoclonal Antibody Therapies and Neurologic Disorders
Arch Neurol 65:1162-1165, Novack,J.C.,et al., 2008

Intravenous Immunoglobulin in Autoimmune Neuromuscular Diseases
JAMA 291:2367-2375, Dalakas,M.C., 2004

Intravenous Immunoglobulin Treatment in Neurologic Disorders
Arch Neurol 56:1025-1027,1032, Sorensen,P.S., 1999

Is the Routine Use of Intravenous Immunoglobulin Treatment in Neurologic Disorders Justified?
Arch Neurol 56:1028-1032, Karussis,D.&Abramsky,O., 1999

Intravenous Immunoglobulin in the Treatment of Autoimmune Neuromuscular Diseases:Present Status and Practical Therapeutic Guidelines
Muscle & Nerve 22:1479-1497, Dalakas,M.C., 1999

Intravenous Immune Globulin Therapy for Neurologic Diseases
Ann Int Med 126:721-730, Dalakas,M.C., 1997

Plasma Exchange and Intravenous Immunoglobulin Treatment of Neuromuscular Disease
Ann Neurol 35:260-268, Thornton,C.A.&Griggs,R.C., 1994

Neurological Events Reported after COVID-19 Vaccines: An Analysis of Vaccine Adverse Event Reporting System
Ann Neurol 91:756-771, Frontera, J.A.,et al, 2022

Severe Neurological Toxicity of Immune Checkpoint Inhibitors: Growing Spectrum
Ann Neurol 87:659-669, Dubey, D.,et al, 2020

Migraine
NEJM 383:1866-1876, Ashina, M., 2020

Neuromuscular Adverse Events Associated with Anti-PD-1 Monoclonal Antibodies
Neurol 92:663-674, Johansen, A.,et al, 2019

Acute demyelinating polyneuropathy induced by nivolumab
JNNP 89:435-437, Fukumoto, Y.,et al, 2018

Inflammatory Demyelinating Polyneuropathy Versus Leptomeningeal Disease Following Ipilimumab
J Immunother Cancer 6:11, Cafuir, L.,et al, 2018

Acute Demyelinating Polyneuropathy Caused by Nivolumab in a Man with Metastatic Non-Small Cell Lung Cancer
J Gerontol Geriatr Res 5:3, Sabeeh-Ur-Rehman, B. & Bhaumik, S., 2016

Neurological, Respiratory, Musculoskeletal, Cardiac and Ocular Side-Effects of Anti-PD-1 Therapy
Eur J Cancer 60:210-225, Zimmer, L.,et al, 2016

Dystonia in Children and Adolescents: A Systematic Review and a New Diagnostic Algorithm
JNNP 86:774-781, Van Egmond, M.E.,et al, 2015

Association between Guillain-Barr� Syndrome and Influenza a (H1N1) 2009 Monovalent Inactivated Vaccines in the USA: A Meta-Analysis
Lancet 381:1461-1468, Salmon, D.,et al, 2013

Neurological Immune-Related Adverse Events of Ipilimumab
Pract Neurol 13:278-280, Bot, I.,et al, 2013

Multimodal Imaging of Reversible Cerebral Vasoconstriction Syndrome: A Series of 6 Cases
AJNR 33:1403-1410, Marder, C.P.,et al, 2012

Spectrum of Neurologic Complications in Chronic Lymphocytic Leukemia
Clin Lymphoma Myeloma Leuk 12:164-179, Lopes da Silva, R., 2012

Reversible Cerebral Vasoconstruction Syndromes
Arch Neurol 68:1005-1012,976, Singhal, A.B.,et al, 2011

Long-Term Course of Demyelinating Neuropathies Occurring During Tumor Necrosis Factor-a-Blocker Therapy
JAMA Neurol 66:490-497, Lozeron, P.,et al, 2009

Polymyalgia Rheumatica
BMJ 336:765-769, Michet,C.J. &Matteson,E.L., 2008

Causative Factors and Epidemiology of Bilateral Vestibulopathy in 255 Patients
Ann Neurol 61:524-532, Zingler,V.C.,et al, 2007

Chronic Inflammatory Demyelinating Polyneuropathy
NEJM 352:1343-1356, Koller,H.,et al, 2005

Neuropathy Resembling CIDP in Patients Receiving Tumor Necrosis Factor-a Blockers
Neurol 64:1468-1470, Richez,C.,et al, 2005

Neurologic Adverse Events Associated With Smallpox Vaccination in the United States, 2002-2004
JAMA 294:2744-2750, Sejvar,J.J.,et al, 2005

Adverse Events Reported Following Live, Cold-Adapted, Intranasal Influenza Vaccine
JAMA 294:2720-2725, Izurieta,H.S.,et al, 2005

Guillain-Barre Syndrome Seen in Users of Isotretinoin
BMJ 328:1537, Pritchard,J.,et al, 2004

Guillain-Barre Syndrome Follwoing Influenza Vaccination
JAMA 292:2478-2481, Haber,P.,et al, 2004

Procainamide-Induced Chronic Inflammatory Demyelinating Polyradiculoneuropathy
Neurol 50:824-825, Erdem,S.,et al, 1998

Pulse Cyclophosphamide Therapy in Chronic Inflammatory Demyelinating Polyneuropathy
Neurol 51:1735-1738, Good,J.L.,et al, 1998

An Acute Neurologic Syndrome Temporally Associated with Postexposure Trtm of Rabies
Pediatrics 100:720-721, Mortiere,M.D.&Falcone,A.L., 1997

Reversible Encephalopathy with Cerebral Vasospasm in a Guillain-Barre Syndrome Patient Treated with Intravenous Immunoglobulin
Neurol 46:250-251, Voltz,R.,et al, 1996

Pilot Trial of Immunoglobulin Versus Plasma Exchange in Patients with Guillain-Barre Syndrome
Neurol 46:100-103, Bril,V.,et al, 1996

Intravenous IgG in Guillain-Barre Syndrome
BMJ 313:376-377, Hughes,R.A.C., 1996

Relapse in Guillain-Barre Syndrome after Treatment with Human Immune Globulin
Neurol 43:872-875, 8571993., Inrani,D.N.,et al, 1993

Human Immune Globulin Infusion in Guillain-Barre Syndrome:Worsening During & After Treatment
Neurol 43:1034-1036, 8571993., Castro,L.H.M.&Ropper,A.H., 1993

Guillain-Barre Syndrome after Exogenous Gangliosides in Italy
BMJ 307:1463-1464, Landi,G.,et al, 1993

GM-1 Ganglioside for Spinal-Cord Injury
NEJM 326:493, Schonhofer,P.S., 1992

Recurrent Aseptic Meningitis Complicating Intravenous Immunoglobulin Therapy for CIDP
Neurol 42:1636-1637, Vera-Ramirez,M.,et al, 1992

Bovine Gangliosides and Acute Motor Polyneuropathy
BMJ 305:1330-1331, Figueras,A.,et al, 1992

Guillain-Barre Syndrome After Streptokinase Therapy
Acta Neurologica Scand 82:153, Roquer,J.,et al, 1990

Postmarketing Surveillance for Neurologic Adverse Events after Hepatitis B Vaccination, Exp of the First 3 Yrs
Am J Epidemiol 127:337-352, Shaw,F.E.,et al, 1988

Autoimmune Encephalitis Misdiagnosis in Adults
JAMA Neurol 80:30-39, Flanagan,E.P.,et al, 2023

New-Onset Diplopia and Headache in a Patient with Metastatic Breast Cancer
Neurol 100:927-931, Rizzo,S.A.,et al, 2023

Cannabis-Related Disorders and Toxic Effects
NEJM 389: 2267-2275, Gorelick,D.A., 2023



Showing articles 0 to 50 of 270 Next >>